Evidence from preclinical studies is most supportive of tumor-modulating roles for insulin, CCK, and Lcn2, whereas data are less conclusive for the adipokines leptin and adiponectin, despite correlations from human epidemiologic studies. Here, CCK is linked to neoplasm.